Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News BiomX Inc. PHGE

Alternate Symbol(s):  PHGE.WS | PHGE.U

BiomX Inc is a clinical-stage microbiome company based in Israel. The company is engaged in developing both natural and engineered phage cocktails designed to target and destroy harmful bacteria that affect the appearance of the skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis.


Recent & Breaking News (NYSEAM:PHGE)

BiomX To Present at H.C. Wainwright 1st Annual Investor Conference on Bacteriophage

GlobeNewswire November 29, 2022

BiomX Reports Third Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire November 9, 2022

BiomX to Host Third Quarter 2022 Financial Results Conference Call and Webcast on November 9, 2022

GlobeNewswire November 2, 2022

BiomX To Present at H.C. Wainwright 24th Annual Global Investment Conference

Business Wire September 11, 2022

BiomX Reports Second Quarter 2022 Financial Results and Provides Business Update

Business Wire August 10, 2022

BiomX to Host Second Quarter 2022 Financial Results Conference Call and Webcast on August 10, 2022

Business Wire August 7, 2022

BiomX Announces Publication in Cell of Research Demonstrating Proof-of-Concept Assessment of Orally Administered Phage Treatment in Preclinical Model of Inflammatory Bowel Disease

Business Wire August 4, 2022

BiomX Announces Voluntary Delisting from the Tel Aviv Stock Exchange

Business Wire July 6, 2022

Boehringer Ingelheim and BiomX Collaborate to Discover Inflammatory Bowel Disease Microbiome Biomarkers

Business Wire June 28, 2022

BiomX Announces Dosing of the First Two Patients in Phase 1b/2a Study of BX004 for Treatment of Chronic Respiratory Infections in Patients with Cystic Fibrosis

Business Wire June 27, 2022

BiomX Announces Corporate Restructuring

Business Wire May 24, 2022

BiomX Announces Publication in the Journal, Bioinformatics

Business Wire May 20, 2022

BiomX Reports First Quarter 2022 Financial Results and Provides Business Update

Business Wire May 11, 2022

BiomX to Host Key Opinion Leader Event on BX004 for Treatment of Pseudomonas Aeruginosa Infections in Cystic Fibrosis Patients

Business Wire May 6, 2022

BiomX to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 11, 2022

Business Wire May 5, 2022

BiomX Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Business Wire March 30, 2022

BiomX to Host Fourth Quarter and Full Year 2021 Financial Results Conference Call and Webcast on March 30, 2022

Business Wire March 23, 2022

BiomX Presenting at Three Upcoming Investor Conferences

Business Wire February 24, 2022

BiomX Announces Therapeutics Development Award of up to $5 Million from the Cystic Fibrosis Foundation

Business Wire January 4, 2022

BiomX Presenting at Two Upcoming Conferences in November

GlobeNewswire November 17, 2021